| Literature DB >> 26460889 |
Jamie Pawlowski1, Laeeq Malik1,2,3, Devalingam Mahalingam1,2,3.
Abstract
This questionnaire-based study assessed the understanding and perceptions of cancer patients who were participating in a Phase I clinical trial at baseline and determined any changes after enrollment. Thirty-six patients participated. Less than one-third of respondents (28.5%) thought the purpose of Phase I trials was dose escalation for safety and efficacy. Patients anticipated varying degree of therapeutic benefit ranging from stable disease (47.1%) to complete shrinkage of the tumor (32.4%). No change in measured themes was observed. Patients participating in Phase I trials need further education to improve their understanding of the true intent of early Phase trials.Entities:
Keywords: Chemotherapy; Clinical trials; Medical ethics
Mesh:
Year: 2015 PMID: 26460889 DOI: 10.3109/07357907.2015.1069833
Source DB: PubMed Journal: Cancer Invest ISSN: 0735-7907 Impact factor: 2.176